[HTML] nature.com

[HTML][HTML] Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

H Liang, Y Xu, J Zhao, M Chen, M Wang - Cancer Gene Therapy, 2024 - nature.com
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …
被引用次数：1 相关文章

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers.

H Liang, Y Xu, J Zhao, M Chen, M Wang - Cancer Gene Therapy, 2024 - europepmc.org
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …
[HTML] nih.gov

[HTML][HTML] Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

H Liang, Y Xu, J Zhao, M Chen, M Wang - Cancer Gene Therapy, 2024 - ncbi.nlm.nih.gov
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers

H Liang, Y Xu, J Zhao, M Chen, M Wang - Cancer gene therapy - pubmed.ncbi.nlm.nih.gov
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …

Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers.

H Liang, Y Xu, J Zhao, M Chen, M Wang - Cancer Gene Therapy, 2024 - europepmc.org
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell
lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the …